GABRB3
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GABRB3</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRB3</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q12</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>chr15:26,700,000-27,100,000 (GRCh38)</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~250 kb</td>
</tr>
<tr>
<td class="label">Number of Exons</td>
<td>10 coding exons</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>473 amino acids (beta-3 subunit)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Ligand-gated ion channel (Cys-loop family)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (thalamus, cortex, hippocampus), widespread CNS</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant (de novo in most cases)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137192</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P28472</td>
</tr>
<tr>
<td class="label">Variant Type</td>
<td>Typical Phenotype</td>
</tr>
<tr>
<td class="label">Missense in N-terminal/EC domain</td>
<td>Childhood absence epilepsy</td>
</tr>
<tr>
<td class="label">Missense in transmembrane domain</td>
<td>Febrile seizures, Dravet-like</td>
</tr>
<tr>
<td class="label">Truncating variants</td>
<td>Severe developmental encephalopathy</td>
</tr>
<tr>
<td class="label">
...
GABRB3
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GABRB3</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRB3</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q12</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>chr15:26,700,000-27,100,000 (GRCh38)</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~250 kb</td>
</tr>
<tr>
<td class="label">Number of Exons</td>
<td>10 coding exons</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>473 amino acids (beta-3 subunit)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Ligand-gated ion channel (Cys-loop family)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (thalamus, cortex, hippocampus), widespread CNS</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant (de novo in most cases)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137192</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P28472</td>
</tr>
<tr>
<td class="label">Variant Type</td>
<td>Typical Phenotype</td>
</tr>
<tr>
<td class="label">Missense in N-terminal/EC domain</td>
<td>Childhood absence epilepsy</td>
</tr>
<tr>
<td class="label">Missense in transmembrane domain</td>
<td>Febrile seizures, Dravet-like</td>
</tr>
<tr>
<td class="label">Truncating variants</td>
<td>Severe developmental encephalopathy</td>
</tr>
<tr>
<td class="label">Whole gene deletion (15q11.2)</td>
<td>EEG abnormalities, developmental delay</td>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Childhood absence epilepsy (CAE)</td>
<td>Missense variants</td>
</tr>
<tr>
<td class="label">Febrile seizures</td>
<td>Missense variants</td>
</tr>
<tr>
<td class="label">Dravet-like epilepsy</td>
<td>Severe missense, truncating</td>
</tr>
<tr>
<td class="label">Early-onset epileptic encephalopathy</td>
<td>Truncating, severe missense</td>
</tr>
<tr>
<td class="label">EEG abnormalities</td>
<td>Copy number variants</td>
</tr>
</table>
[GABRB3](/entities/gabrb3) encodes the beta-3 subunit of the GABA-A receptor, a ligand-gated chloride channel responsible for fast synaptic inhibition in the central nervous system. The beta-3 subunit is a critical component of many GABA-A receptor subtypes, including the predominant benzodiazepine-sensitive receptors in the thalamus and cortex. Pathogenic variants in [GABRB3](/entities/gabrb3) cause childhood absence epilepsy, febrile seizures, and Dravet-like phenotypes, with a spectrum ranging from mild epilepsy to severe developmental encephalopathy. PMID: 39241780
[GABRB3](/entities/gabrb3) maps to chromosome 15q12, within the same imprinted region as [UBE3A](/entities/ube3a). However, in contrast to UBE3A, GABRB3 is not imprinted in the brain — it is biallelically expressed. The proximity to the Angelman syndrome imprinted locus means that some patients with 15q11.2 deletions may have GABRB3 haploinsufficiency contributing to their phenotype. PMID: 39475571
Structure and Function
GABA-A Receptor Architecture
GABA-A receptors are pentameric ligand-gated chloride channels composed of five subunits arranged around a central pore: PMID: 26250687
- Subunit composition: Most native GABA-A receptors contain two alpha, two beta, and one gamma or delta subunit
- Beta-3 subunit role: Beta subunits form the backbone of the receptor and are essential for:
- Proper receptor assembly and trafficking
- GABA binding site formation (beta subunits contribute to each of the two GABA binding interfaces)
- Benzodiazepine sensitivity (receptors with alpha1/2/3/5 + beta + gamma2 are BZ-sensitive) PMID: 29874566
- Channel gating and conductance
Receptor Subtypes Containing Beta-3
Key GABA-A receptor subtypes containing the beta-3 subunit:
- Alpha1beta3gamma2: Most abundant in cortex and thalamus; primary target of many ASMs and BZDs
- Alpha2beta3gamma2: Expressed in hippocampus and amygdala; important for anxiolytic effects
- Alpha3beta3gamma2: Expressed in cortical and thalamic neurons
- Alpha5beta3delta: Expressed extrasynaptically in hippocampus PMID: 32755557
Function in Inhibition
GABA binding to the beta-3-containing receptor:
Opens the central chloride channel
Chloride influx hyperpolarizes the neuron
Reduces neuronal firing probability
Provides fast, phasic inhibition at synapsesPathophysiology in GABRB3 Epilepsy
Variant Types and Mechanisms
Pathogenic [GABRB3](/entities/gabrb3) variants cause epilepsy through two primary mechanisms:
1. Reduced receptor function (loss-of-function):
- Truncating variants reduce beta-3 subunit expression
- Missense variants impair assembly, trafficking, or gating
- Result: fewer functional GABA-A receptors → reduced inhibitory current → hyperexcitability
2. Altered receptor properties (gain-of-function or dominant-negative):
- Some missense variants cause receptors to open inappropriately
- May lead to constant low-level chloride influx or altered kinetics
- Result: disrupted inhibition timing → network instability
Thalamocortical Dysfunction
GABRB3 is highly expressed in the thalamus, where it plays a critical role in the thalamocortical circuits underlying absence seizures:
- T-type calcium channels (Cav3.1) and GABA-B GPCRs drive burst firing in thalamic relay neurons
- GABA-A receptors (including beta-3-containing) provide feedforward and feedback inhibition
- Loss of beta-3 disrupts thalamic inhibition, promoting the aberrant spike-wave oscillations characteristic of absence epilepsy
Genotype-Phenotype Correlations
Disease Associations
Therapeutic Approaches
Current Management
Standard ASMs used with variable efficacy:
- Ethosuximide: first-line for absence component; works by blocking T-type Ca channels
- Valproic acid: broad-spectrum; often effective for generalized seizures
- Clobazam: adjunct for myoclonic/atonic components
- Carbamazepine: AVOID — can worsen absence and myoclonic seizures
Gene Therapy Considerations
GABRB3 is a reasonable gene therapy target given:
- Monogenic cause in affected patients
- Clear loss-of-function mechanism
- Well-characterized functional consequences
- Gene size (~1.4 kb coding) fits easily in AAV
Delivery approaches:
- AAV9/AAV5 targeting neurons
- Neuronal-specific promoter (synapsin, CaMKII)
- ICV or intrathecal delivery for broad CNS distribution
- Potential for intranasal delivery (emerging approaches)
Therapeutic goal: Restore sufficient beta-3 subunit expression to produce functional GABA-A receptors capable of mediating normal inhibitory currents.
Preclinical Status
GABRB3 gene therapy programs are in early preclinical development. Key considerations:
- Appropriate mouse models: Gabrb3 knockout and conditional knock-in mice exist
- Neonatal vs. adult delivery to assess critical period
- Dose-response studies for seizure and behavioral outcomes
- Delivery optimization for thalamic targeting
See [therapeutics hub page](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy) for more on the GABRB3 gene therapy landscape.
Research and Open Questions
Subunit compensation — are beta-1 or beta-2 subunits upregulated as compensation in Gabrb3 variants?
Thalamic targeting — what delivery route achieves the best beta-3 expression in thalamus?
Optimal timing — when is the critical period for GABRB3 intervention in humans?
Dosing threshold — what percentage of wild-type beta-3 levels is sufficient for clinical benefit?
Biomarkers — EEG signatures, GABA-A receptor density imaging, or biochemical markers for pharmacodynamics?
BZD sensitivity — do patients with GABRB3 variants show altered benzodiazepine sensitivity?
Imprinting context — does GABRB3 function differ in patients with 15q11.2 deletions vs. point mutations?References
[@gabrb3_2013] [GABRB3 and childhood absence epilepsy: genetics and functional consequences](https://pubmed.ncbi.nlm.nih.gov/23569124/)
[@gabrb3_2016] [De novo GABRB3 mutations cause severe early-onset epilepsy](https://pubmed.ncbi.nlm.nih.gov/27339979/)Pathway Diagram
The following diagram shows the key molecular relationships involving GABRB3 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving GABRB3 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)